**Dingemanse 1998** Dingemanse J, Wallnöfer A, Gieschke R, Guentert T, Amrein R. Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the “serotonin syndrome”. Clin Pharmacol Ther. 1998;63(4):403-413.

**DrugBank DB01171** (https://www.drugbank.ca/drugs/DB01171)

**Gram 1995** Gram LF, Guentert TW, Grange S, Vistisen K, Brøsen K. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study. *Clinical Pharmacology & Therapeutics*. 1995 Jun;57(6):670–7.

**Guentert 1990** Guentert TW, Tucker G, Korn A, Pfefen JP, Haefelfinger P, Schoerlin MP. Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days. Acta Psychiatr Scand. 1990;82(S360):91-93.

**Hoskins 2001** Hoskins J, Shenfield G, Murray M, Gross A. Characterization of moclobemide N -oxidation in human liver microsomes. Xenobiotica. 2001 Jan;31(7):387–97.

**IPCS ICHEM** Website: inchem.org/documents/pims/pharm/pim151.htm#SectionTitle:3.3%20%20Physical%20properties

**Ignjatovic 2009** Ignjatovic AR, Miljkovic B, Todorovic D, Timotijevic I, Pokrajac M. Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: A pharmacokinetic interaction study. Br J Clin Pharmacol. 2009;67(2):199-208.

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531.

**Kramer-Nielsen 1996 ** Kramer-Nielsen KK, Flinois JP, Beaune P, Brøsen K. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. *J Pharmacol Exp Ther*. 1996 Jun;277(3):1659–64.

**Mayersohn 1995**  Mayersohn M, Guentert TW. Clinical Pharmacokinetics of the Monoamine Oxidase-A Inhibitor Moclobemide*, Clinical Pharmacokinetics*. 1995 Nov;29(5):292–332.

**MHRA Label Moclobemide ** MHRA label of Moclobemide film-coated tablets. Website: mhra.gov.uk/home/groups/par/documents/websiteresources/con097060.pdf

**Moclobemide, INCHEM**, Website inchem.org/documents/pims/pharm/pim151.htm#PartTitle:3.%20%20PHYSICO-CHEMICAL%20PROPERTIES

**Nair 1993** Nair NPV, Ahmed SK, Ng Ying Kin NMK. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: Focus on moclobemide. *J Psychiatry Neurosci*. 1993;18(5):214-225.

**PK-Sim Ontogeny Database Version 7.3** (https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf)

**Pons 1990** Pons G, Schoerlin MP, Tam Y. Moclobemide excretion in human breast milk. *Br J Clin Pharmacol*. 1990;29(1):27–31.

**Raaflaub 1984** Raaflaub J, Haefelfinger P, Trautmann KH. Single-dose Pharmacokinetics of the MAO-Inhibitor Moclobemide in Man. *Drug Res*. 1984; 34:80–2.

**Schoerlin 1987** Schoerlin M-P, Mayersohn M, Korn A, Eggers H. Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: Single and multiple dosing in normal subjects. *Clinical Pharmacology and Therapeutics*. 1987 Oct;42(4):395–404.

**Wiesel 1985** Wiesel FA, Raaflaub J, Kettler R. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. Eur J Clin Pharmacol. 1985;28(1 Supplement):89-95.

**Willmann 2007** Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. *J Pharmacokinet Pharmacodyn* 2007, 34(3): 401-431.

**Wu 2014** Wu F, Gaohua L, Zhao P, Jamei M, Huang S-M, Bashaw ED, et al. Predicting Nonlinear Pharmacokinetics of Omeprazole Enantiomers and Racemic Drug Using Physiologically Based Pharmacokinetic Modeling and Simulation: Application to Predict Drug/Genetic Interactions. *Pharmaceutical Research*. 2014 Aug;31(8):1919–29.

**Yu 2001** Yu K, Yim DS, Cho J-Y, Park SS. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clinical Pharmacology & Therapeutics. 2001 Apr;69(4):266–73.
